{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol
to a specific field?
Status:
Investigational
Source:
NCT04722991: Phase 2 Interventional Completed Diabetic Retinopathy
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01893125: Phase 2 Interventional Completed Diabetic Peripheral Neuropathy
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:ivarmacitinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:izilendustat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03239691: Phase 2 Interventional Completed Photosensitive Epilepsy
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glaspimod (SK&F 107647) is a synthetic hematoregulatory peptide that shares biological and/or modulatory activities with natural hematopoietic cytokines. The peptide has been tested in vitro and in vivo for hematopoietic effects (involvement in production of cellular blood components). In vitro, glaspimod has no direct colony-stimulating activity (CSA), In vivo, injection of the compound results in an increase in serum CSA (maximal at 6 hours after injection). With repeated administration, significant increases in absolute numbers of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells can be measured. Pharmacokinetic effects of glasmipod have been studied in patients with adenocarcinoma and were not amenable to standard therapy.
Status:
Investigational
Source:
JAN:PRADIMOTIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00671736: Phase 2 Interventional Completed Cystic Fibrosis
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LANCOVUTIDE, also known as duramycin, is a 19-amino-acid tetracyclic peptide antibiotic. It is in clinical development for the treatment of cystic fibrosis (CF). It activates an alternative chloride channel in lung epithelial cells by elevating intracellular calcium levels, and may potentially compensate for CF transmembrane conductance regulator deficiency in the airway epithelium and increase the volume of the airway surface liquid.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Basifungin, previously known as LY 295337 or aureuobacidin A, is an antifungal agent that inhibits phosphorylceramide synthase. The development of basifungin against mycoses was discontinued.
Status:
Investigational
Source:
NCT03369262: Phase 2 Interventional Unknown status Preterm Labor
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
